Prediction of off-target effects on angiotensin-converting enzyme 2

Journal of Biomolecular Screening

Volumn 16, Issue 8, 2011, Pages 878-885

  Kulemina, Lidia V ^a   Ostrov, David A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cardiac diseases; Chemoinformatics; Compound repositories; Computational chemistry; General pharmaceutical process

Indexed keywords

1 (2 DIETHYLAMINOETHYLAMINO) 4 (HYDROXYMETHYL)THIOXANTHEN 9 ONE; 1 [[2 DIMETHYLAMINETHYL]AMINO] 4 (HYDROXYMETHYL) 7 [[(4 METHYLPHENYL)SULFONYL]OXY] 9H XANTHEN 9 ONE; 2 [2 [4 [(4 CHLOROPHENYL)PHENYLMETHYL]PIPERAZIN 1 YL]ETHOXY]ETHANOL; 2 HYDROXY 5 [1 HYDROXY 2 (4 PHENYLBUTAN 2 YLAMINO)ETHYL]BENZAMIDE; 3 (2 CHLOROTHIOXANTHEN 9 YLIDENE) N,N DIMETHYLPROPAN 1 AMINE; 4 [2 (4 CARBAMIMIDOYLPHENYL)IMINOHYDRAZINYL]BENZENECARBOXIMIDAMIDE; 5 CHLORO 3 [2 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YL] 2 OXOETHYL] 1,3 BENZOTHIAZOL 2 ONE; 8 [3 (2 CHLOROPHENOTHIAZIN 10 YL)PROPYL] 4 THIA 1,8 DIAZASPIRO[4.5]DECAN 2 ONE; ANGIOTENSIN CONVERTING ENZYME 2; DIMINAZENE; N [4 CHLORO 2 [[METHYL(2 MORPHOLIN 4 YL 2 OXOETHYL)AMINO]METHYL]PHENYL]BENZAMIDE; N' (2,3 DIHYDRO 1H INDEN 2 YL) N,N DIETHYL N' PHENYLPROPANE 1,3 DIAMINE; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CATALYSIS; CONFORMATION; CRYSTAL STRUCTURE; DRUG APPROVAL; ENZYME KINETICS; FOOD AND DRUG ADMINISTRATION; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VASODILATATION;

ANGIOTENSIN II; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMINAZENE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYPERTENSION; KINETICS; MODELS, MOLECULAR; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; PRESCRIPTION DRUGS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY; THERMODYNAMICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80054719529     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057111413919     Document Type: Article

References (31)

1. Kuntz, I. D. Structure-Based Strategies for Drug Design and Discovery. Science 1992, 257, 1078-1082.
2. Lindsley, C. W. The Akt/PKB Family of protein Kinases: A Review of small Molecule Inhibitors and Progress towards Target Validation: A 2009 Update. Curr. Top. Med. Chem. 2010, 10, 458-477.
3. Li, H. F.; Chen, Y.; Rao, S. S.; Chen, X. M.; Liu, H. C.; Qin, J. H.; Tang, W. F.; Yue, W.; Zhou, X.; Lu, T. Recent Advances in the Research and Development of B-Raf Inhibitors. Curr. Med. Chem. 2010, 17, 1618-1634.
4. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore Based Drug Design Approach as a practical process in Drug Discovery. Curr. Comput. Aided Drug. Des. 2010, 6, 37-49.
5. Villoutreix, B. O.; Eudes, R.; Miteva, M. A. Structure-Based Virtual Ligand Screening: Recent Success Stories. Comb. Chem. High Throughput Screen. 2009, 12, 1000-1016.
6. Talele, T. T.; Khedkar, S. A.; Rigby, A. C. Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic. Curr. Top. Med. Chem. 2010, 10, 127-141.
7. Annane, D. Improving Clinical Trials in the Critically Ill: Unique Challenge-Sepsis. Crit. Care Med. 2009, 37, S117-S128.
8. Staessen, J. A.; Richart, T.; Wang, Z.; Thijs, L. Implications of Recently published Trials of Blood pressure-Lowering Drugs in Hypertensive or High-Risk patients. Hypertension 2010, 55, 819-831.
9. Verdecchia, P.; Gentile, G.; Angeli, F.; Mazzotta, G.; Mancia, G.; Reboldi, G. Influence of Blood pressure Reduction on Composite Cardiovascular Endpoints in Clinical Trials. J. Hypertens. 2010, 25, 1356-1365.
10. Bonomi, P. D. Implications of Key Trials in Advanced Nonsmall Cell Lung Cancer. Cancer 2010, 116, 1155-1164.
11. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; et al. A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circ. Res. 2000, 57, E1-E9.
12. Tipnis, S. R.; Hooper, N. M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A. J. A Human Homolog of Angiotensin-Converting Enzyme: Cloning and Functional Expression as a Captopril-Insensitive Carboxypeptidase. J. Biol. Chem. 2000, 275, 33238-33243.
13. Hernandez Prada, J. A.; Ferreira, A. J.; Katovich, M. J.; Shenoy, V.; Qi, Y.; Santos, R. A.; Castellano, R. K.; Lampkins, A. J.; Gubala, V.; Ostrov, D. A., et al. Structure-Based Identification of Small-Molecule Angiotensin- Converting Enzyme 2 Activators as Novel Antihypertensive Agents. Hypertension 2008, 51, 1312-1317. (Pubitemid 351555943)
14. Ferreira, A. J.; Shenoy, V.; Yamazato, Y.; Sriramula, S.; Francis, J.; Yuan, L.; Castellano, R. K.; Ostrov, D. A.; Oh, S. P.; Katovich, M. J.; Raizada, M. K. Evidence for Angiotensin-Converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension. Am. J. Respir. Crit. Care Med. 2009, 179, 1048-1054.
15. Towler, P.; Staker, B.; prasad, S. G.; Menon, S.; Tang, J.; Parsons, T.; Ryan, D.; Fisher, M.; Williams, D.; Dales, N. A.; et al. ACE2 X-Ray Structures Reveal a Large Hinge-Bending Motion Important for Inhibitor Binding and Catalysis. J. Biol. Chem. 2004, 279, 17996-18007. (Pubitemid 38560569)
16. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L. III. Assessing Scoring Functions for Protein-Ligand Interactions. J. Med. Chem. 2004, 47, 3032-3047. (Pubitemid 38702700)
17. Gschwend, D. A.; Good, A. C.; Kuntz, I. D. Molecular Docking towards Drug Discovery. J. Mol. Recognit. 1996, 9, 175-186. (Pubitemid 26369496)
18. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: Search Strategies for Automated Molecular Docking of Flexible Molecule Databases. J Comput. Aided Mol. Des. 2001, 15, 411-428. (Pubitemid 32452109)
19. Driscoll, J. S. The Preclinical New Drug Research Program of the National Cancer Institute. Cancer Treat. Rep. 1984, 65, 63-76. (Pubitemid 14192160)
20. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605-1612.
21. Palmier, M. O.; Van Doren, S. R. Rapid Determination of Enzyme Kinetics from Fluorescence: Overcoming the Inner Filter Effect. Anal. Biochem. 2007, 371, 43-51. (Pubitemid 47538482)
22. Elased, K. M.; Cunha, T. S.; Gurley, S. B.; Coffman, T. M.; Morris, M. New Mass Spectrometric Assay for Angiotensin-Converting Enzyme 2 Activity. Hypertension 2006, 47, 1010-1017. (Pubitemid 44297576)
23. Williams-DeVane, C. R.; Wolf, M. A.; Richard, A. M. DSSTox Chemical-Index Files for Exposure-Related Experiments in ArrayExpress and Gene Expression Omnibus: Enabling Toxico-Chemogenomics Data Linkages. Bioinformatics 2009, 25, 692-694.
24. Ahuja, K.; Charap, M. H. Management of Perioperative Hypertensive Urgencies with Parenteral Medications. J. Hosp. Med. 2010, 5, E11-E16.
25. Jorde, U. P.; Ennezat, P. V.; Lisker, J.; Suryadevara, V.; Infeld, J.; Cukon, S.; Hammer, A.; Sonnenblick, E. H.; Le Jemtel, T. H. Maximally Recommended Doses of Angiotensin-Converting Enzyme (ACE) Inhibitors Do Not Completely Prevent ACE-Mediated Formation of Angiotensin II in Chronic Heart Failure. Circulation 2000, 101, 844-846. (Pubitemid 30117877)
26. Hanon, S.; Vijayaraman, P.; Sonnenblick, E. H.; Le Jemtel, T. H. Persistent Formation of Angiotensin II Despite Treatment with Maximally Recommended Doses of Angiotensin Converting Enzyme Inhibitors in Patients with Chronic Heart Failure. J. Renin Angiotensin Aldosterone Syst. 2000, 1, 147-150.
27. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.; Hsieh, F.; et al. Hydrolysis of Biological Peptides by Human Angiotensin-Converting Enzyme-Related Carboxypeptidase. J. Biol. Chem. 2002, 277, 14838-14843. (Pubitemid 34952556)
28. Schindler, C.; Bramlage, P.; Kirch, W.; Ferrario, C. M. Role of the Vasodilator Peptide Angiotensin-(1-7) in Cardiovascular Drug Therapy. Vasc. Health Risk. Manag. 2007, 3, 125-137. (Pubitemid 46860722)
29. Valerio, L. G.; Yang, C.; Arvidson, K. B.; Kruhlak, N. L. A Structural Feature-Based Computational Approach for Toxicology Predictions. Expert Opin. Drug Metab. Toxicol. 2010, 6, 505-518.
30. Natesh, R.; Schwager, S. L.; Sturrock, E. D.; Acharya, K. R. Crystal Structure of the Human Angiotensin-Converting Enzyme-Lisinopril Complex. Nature 2003, 421, 551-554. (Pubitemid 36168450)
31. Mores, A.; Matziari, M.; Beau, F.; Cuniasse, P.; Yiotakis, A.; Dive, V. Development of Potent and Selective Phosphinic Peptide Inhibitors of Angiotensin-Converting Enzyme 2. J. Med. Chem. 2008, 51, 2216-2226. (Pubitemid 351503277)